Activity of cytisine and its brominated isosteres on recombinant human a7, a4b2 and a4b4 nicotinic acetylcholine receptors
Artículo
Open/ Download
Publication date
2001-06-06Metadata
Show full item record
Cómo citar
Houlihan, Lee M.
Cómo citar
Activity of cytisine and its brominated isosteres on recombinant human a7, a4b2 and a4b4 nicotinic acetylcholine receptors
Author
Abstract
Effects of cytisine (cy), 3-bromocytisine (3-Br-cy), 5-bromocytisine
(5-Br-cy) and 3,5-dibromocytisine (3,5-diBr-cy) on
human (h) a7-, a4b2- and a4b4 nicotinic acetylcholine (nACh)
receptors, expressed in Xenopus oocytes and cell lines, have
been investigated. Cy and its bromo-isosteres fully inhibited
binding of both [a-125I]bungarotoxin ([a-125I]BgTx) to ha7- and
[3H]cy to ha4b2- or ha4b4-nACh receptors. 3-Br-cy was the
most potent inhibitor of both [a-125I]BgTx and [3H]cy binding.
Cy was less potent than 3-Br-cy, but 5-Br-cy and 3,5-diBr-cy
were the least potent inhibitors. Cy and 3-Br-cy were potent
full agonists at ha7-nACh receptors but behaved as partial
agonists at ha4b2- and ha4b4-nACh receptors. 5-Br-cy and
3,5-diBr-cy had low potency and were partial agonists at ha7-
and ha4b4-nACh receptors, but they elicited no responses on
ha4b2-nACh receptors. Cy and 3-Br-cy produced dual
dose±response curves (DRC) at both ha4b2- and ha4b4-
nACh receptors, but ACh produced dual DRC only at
ha4b2-nACh receptors. Low concentrations of cy, 3-Br-cy
and 5-Br-cy enhanced ACh responses of oocytes expressing
ha4b2-nACh receptors, but at high concentrations they
inhibited the responses. In contrast, 3,5-diBr-cy only inhibited,
in a competitive manner, ACh responses of ha4b2-nACh
receptors. It is concluded that bromination of the pyridone ring
of cy produces marked changes in effects of cy that are
manifest as nACh receptor subtype-specific differences in
binding af®nities and in functional potencies and efficacies
Patrocinador
Work in Phoenix toward this
project, part of which was conducted in the Charlotte and
Harold Simensky Neurochemistry of Alzheimer's Disease
Laboratory, was supported by endowment and/or capitalization
funds from the Men's and Women's Boards of the Barrow
Neurological Foundation, the Robert and Gloria Wallace
Foundation, and Epi-Hab Phoenix, Inc., and by grants from
the Arizona Disease Control Research Commission (9903) and
the Council for Tobacco Research ± USA (4366).
Quote Item
Journal of Neurochemistry, Vol. 78, p. 1029-1043, 2001
Collections